Among the 7 patients who discontinued their initial EGFR‐TKI due to AEs, 5 were re‐challenged with EGFR‐TKI therapy, of whom 2 subsequently discontinued because of AEs (rash with erlotinib [n = 1], ILD with osimertinib [n = 1]). This evidence concerns the gene EGFR and interstitial lung disease.